SlowBull
The market, slowly. THURSDAY, 24 SEPTEMBER 2026
← All news
Markets

AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease

1 source ·1 article ·Aug 28, 14:58 UTC Atrium Therapeutics Astrazeneca

Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for TTR cardiomyopathy and amplified investor pressure on Alnylam.

Covered by 1 outlet

Biopharmadive 1

All coverage · 1 article

BioPharma Dive ·Aug 28, 14:58 UTC

AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease

Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for TTR cardiomyopathy and amplified investor pressure on Alnylam.